Center for Observational and Real World Evidence, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Adelphi Values PROVE, Bollington, UK.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2054602. doi: 10.1080/21645515.2022.2054602. Epub 2022 Apr 21.
Life-course immunization holds significant benefit for population health by reducing the burden of vaccine-preventable diseases (VPD) through vaccinating individuals at different stages and circumstances in life. The study aimed to determine the epidemiologic, clinical, economic, and societal burden of VPDs among at-risk adult subpopulations in the United States. A systematic literature review was conducted for articles published between January 2010 and June 2020, which identified 72 publications. There was heterogeneity in available epidemiology data, with the prevalence of VPDs ranging from 1.1% to 68.7%. Where the disease burden was described, outcomes were typically worse among high-risk subpopulations than in the general population. Several VPDs, including herpes zoster, meningococcal, and pneumococcal infections were associated with increased costs. This review suggests that subpopulations may not frequently interact with the healthcare system, or their risk factors may not be recognized by healthcare providers, and therefore individuals may not be appropriately targeted for vaccination.
人生全程免疫通过在生命的不同阶段和情况下为个人接种疫苗，减少疫苗可预防疾病（VPD）的负担，对人口健康具有重要意义。本研究旨在确定美国高危成年亚人群中 VPD 的流行病学、临床、经济和社会负担。对 2010 年 1 月至 2020 年 6 月期间发表的文章进行了系统的文献综述，确定了 72 篇出版物。现有流行病学数据存在异质性，VPD 的患病率从 1.1%到 68.7%不等。在描述疾病负担的地方，高危亚人群的结局通常比一般人群更差。几种 VPD，包括带状疱疹、脑膜炎球菌和肺炎球菌感染，与成本增加有关。这篇综述表明，亚人群可能不会经常与医疗保健系统互动，或者他们的风险因素可能没有被医疗保健提供者识别，因此个人可能没有被适当地针对疫苗接种。
